But in general, turning a peptide (including GLP-1 or insulin) into an oral formulation means overcoming three major challenges: protecting the peptide from digestion in the stomach, improving absorption of the peptide via the gut, and slowing down the enzymatic breakdown and excretion of the peptide once it is in the blood
differentiation from pseudoseizure pseudoseizure (technical terminology varies, including Paroxysmal Non-Epileptic Seizures or psychogenic, non-epileptic attacks or functional seizures) A clinical phenomenon that mimics a seizure, often related to psychiatric stress
This is a workflow argument, not an efficacy argument, and it is the most defensible reason a lab would choose a blend at all
It interacts with sweet taste receptors present in enteroendocrine L cells
There are long-term side effects too (Ozempic face - loose, saggy, aging skin)
No coaching but rock-solid medication access